Kembs, France

Jean-Louis Reber

USPTO Granted Patents = 2 


 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2009-2012

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Jean-Louis Reber

Introduction

Jean-Louis Reber is a notable inventor based in Kembs, France. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative patents. With a total of 2 patents, Reber's work focuses on compounds that have potential therapeutic applications.

Latest Patents

Reber's latest patents include the development of quinolinone derivatives and their pharmaceutical compositions. These compounds are designed to treat diseases mediated by the β-adrenoreceptor. The patent details compounds of formula I in salt or solvate form, which are useful in various medical applications. Another significant patent involves malic acid addition salts of terbinafine. This invention concerns the preparation of salts of the compound of formula I with malic acid, their corresponding pharmaceutical compositions, and their use as antimycotics.

Career Highlights

Throughout his career, Jean-Louis Reber has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Novartis AG and Irm LLC. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Reber has collaborated with several professionals in his field, including Danielle Giron and Stefan Hirsch. These partnerships have likely enhanced his research and development efforts, leading to successful patent applications.

Conclusion

Jean-Louis Reber's contributions to pharmaceutical innovations demonstrate his commitment to advancing medical science. His patents reflect a deep understanding of complex compounds and their potential applications in treating various diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…